Lonza Group AG

Lonza Group AG is a leading Swiss multinational specializing in contract development and manufacturing for the healthcare sector. As one of the world’s largest contract development and manufacturing organizations (CDMOs), Lonza partners with pharmaceutical, biotechnology, and specialty ingredient companies to bring life-enhancing therapies to market. The company’s core activities include the development and manufacture of biopharmaceuticals, small molecule drug substances, and advanced therapies such as cell and gene treatments. Its portfolio spans integrated biologics, advanced synthesis, and specialized modalities, addressing client needs from early development through to commercial-scale manufacturing. Lonza leverages its extensive global network, operating more than 30 sites across multiple continents, and employs approximately 18,000 people. Recent strategic moves include a focus on its CDMO business and divestment from capsules and health ingredients, aiming to streamline operations and concentrate on industry-leading offerings such as monoclonal antibodies and cutting-edge biologics. Lonza’s established expertise and innovation-driven approach have made it a pivotal partner in advancing modern medicines worldwide.